Oncotype DX AR-V7 Nucleus Detect is now covered by Medicare for your mCRPC patients
The Oncotype DX AR-V7 Nucleus Detect test is covered by Medicare for patients with metastatic castration-resistant prostate cancer (mCRPC) who may benefit from continued androgen receptor signaling inhibitor (ARSi) therapy, such as enzalutamide, abiraterone and apalutamide, as well as those who are resistant who may benefit from chemotherapy. Since private insurance coverage can vary across the country, it’s a good idea to check with your patient’s insurance carrier or contact the team to confirm coverage. In addition, Genomic Health created the Genomic Access Program (GAP) to help patients navigate insurance and other payment options for Oncotype DX tests. Genomic Health Customer Service
Genomic Health believes that everyone should have access to the information they need to make confident, informed decisions about their cancer treatments.
The GAP team can:
- Contact insurance companies on patients’ behalf.
- Work with clinicians to get prior authorization from insurance companies (if required).
- Bill insurance companies directly when possible.
- Process the claim once the test is complete.
- With your consent, assist in the appeal process if a claim is denied.
Genomic Health offers financial assistance programs for eligible patients with financial hardship. These programs are based on financial eligibility. Contact Customer Service by phone at 866-ONCOTYPE (866-662-6897) or by email to email@example.com for more information.